BioAtla (BCAB) announced presentation of a poster entitled “Targeting HPV E6/E7 Upregulation of the Transmembrane Receptor Tyrosine Kinase ROR2 with the ADC Ozuriftamab Vedotin in Patients with Advanced HPV+ Oropharyngeal Squamous Cell Carcinoma, OPSCC” which details clinical data from its investigational antibody-drug conjugate, ozuriftamab vedotin, Oz-V, at the International Papillomavirus Society Conference, taking place October 23-26, 2025, in Bangkok, Thailand.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCAB: